HYD LLC. for Cancer Research and Drug Development was established in 1993 for the development and worldwide marketing of drugs and consumer products primarily for the prevention and treatment of various kinds of cancer, that utilize a novel proprietary procedure, deuterium depletion. Deuterium depletion is a completely original approach to inhibit the growth of cancer cells in the body and to influence other physiological processes offering a completely safe, non-invasive at the same time a highly effective treatment modality.
All research and development, including drug registration and other product development, based on deuterium depletion technology is exclusively managed, organised and financed by HYD LLC. Different applications of deuterium depletion are protected by international patents and patent applications in most of the developed countries.
In recent years HYD entered the international market, the professional reputation and international recognition of the patent-protected deuterium depletion technology continues to grow. Research has started in several foreign countries in academic institutions, universities and cancer centers.
The milestones of HYD’s history, and its major achievements, prizes and acknowledgements, are as follows:
1995 – HYD LLC started its first human phase II clinical investigation on patients with prostate cancer.
1996 – The patent of HYD won a price at the patent exhibition Genius ’96.
1998 – The patent of HYD won a price at the patent exhibition Genius First Inventors’ Olympic Games.
1999 – HYD LLC. completed the development and registration of its new veterinary drug, Vetera-DDW-25® A.U.V., for the treatment of households pets with tumors.
2000 – The new formulation of deuterium-depleted drinking water protected by the international Preventa® trademarks was placed on the market.
2002 – HYD LLC was rewarded as the 9th fastest developing company of the Central and East European Region in the competition announced by Deloitte & Touche international auditor company. In the region comprising Europe, Middle East and Africa, HYD had the 40th place. The price was delivered to the leaders of the first 500 companies in November 2002 in London.
2003 – HYD LLC had the opportunity to introduce itself on EuroNews TV, the program was broadcast in five languages.
2005 – Preventa® deuterium-depleted drinking water, developed by HYD, won the first prize at the international innovation contest “New Foods”. The jury especially emphasized the importance of the research and the products based on deuterium-depleted water in health preservation.
2009 – In October 2009, HYD LLC opened its first store in Budapest. Beyond selling Preventa® product family, the place was home of high-level professional events.
2010 – HYD organized the First International Symposium on Deuterium Depletion in Budapest. Leading scientists of four countries (Hungary, USA, Russia, Iran) presented their results on research and various applications of deuterium depletion. The aim of the two-day symposium was to present the results of research on deuterium depletion, and to determine the present and future place and role of the procedure in anticancer research and therapy, and in research on diabetes and aging.
2011 – HYD LLC opened its second store in BAH Center Office Building in Budapest.
2012 – At the Second International Congress on Deuterium Depletion, organized by HYD, scientists of seven countries (USA, France, China, Russia, Turkey, Romania, Hungary) presented their results on research and practical application of deuterium depletion.
2012 – Primus Capital closed a HUF 400 Million HUF investment in HYD Pharma Ltd. The investment is being used for validation of research results, and for implementation of a new human phase II clinical test.
2014 – The Preventa brand and product design was renewed, the new product line and the latest packaging materials met the highest consumer expectations. The product line has been marketed in a unique bottle with self-adhesive foil label, and the distinction between different deuterium-based Preventa products was enhanced by the unique color coding features of the product family.
2015 – The 3rd International Congress on Deuterium Depletion was held in May 2015 in Budapest, Hungary. At the conference leading scientists from seven countries (USA, France, Spain, United Kingdom, Russia, Sweden, Hungary) presented and discussed current advances in the research and various application of deuterium depletion.
Following a successful audition by the Hungarian National Institute of Pharmacy and Nutrition in May, 2015, Trigon Biotechnology Inc., strategic partner of the mother company of HYD LLC, HYD Pharma Inc., has received new GMP compliance certificates for the deuterium-depleted water (DDW) producing facility of HYD Pharma.
DDW as Active Pharmaceutical Ingredient was also registered at the European Medicine Agency (EMA) and an EudraCT number 2015-003820-30 was issued for the Protocol Code Number HYD-HD85/45-CLL-02.
2016 – HYD Pharma Inc. was granted ethical approval by the State Institute for Drug Control (SIDC) in Slovakia for Phase 2 as one-of-the-first clinical trials to prove the anticancer effect of deuterium-depleted water (DDW) in chronic lymphocytic leukemia (CLL).
In 2016, Preventa® deuterium-depleted drinking water product line was awarded with the MagyarBrands honorable award in the Outstanding Consumer Brand category.
2019 – The 4th International Congress on Deuterium Depletion took place between 17-18 October 2019, in Budapest. The two-day conference aimed at presenting the newest research outcomes and clinical applications of deuterium depletion, and determining the present and future role of the process in antitumor research and prevention, as well as in the treatment of other, primarily metabolic, diseases, and in the research of aging.
The conference provided a broad scientific forum for domestic and foreign researchers and doctors in this field to share their latest results. By bringing the leading scientists of deuterium depletion of the world together, the conference was, beyond science, also a forum for establishing connections and collaborations.
2020 – The first deuterium-depleted dietary supplement was put in circulation. Preventa deuterium-depleted oyster mushroom extract is the only 100% natural product of oyster mushrooms that is produced in cultivation using water with reduced deuterium content of 85 ppm.
Directorate of Veterinary Products of the National Food Chain Safety Agency gave permission for the clinical investigation of Vetera-DDW-25 A.U.V. injection formula in dogs with breast tumors.